NCT05590468View on ClinicalTrials.gov

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Mitochondrial Myopathy
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

Ralitza Gavrilova

OTHER